The Cutting Edge of Cancer Innovation

Oncolytics is a biotechnology company developing REOLYSIN®, an immuno-oncology viral-agent, as a potential treatment for a variety of tumor types.  The Company is listed on the Toronto Stock Exchange (TSX:ONC) and quoted on the OTCQX® Best Market (OTCQX:ONCYF).  In addition to the information available on this site, investors can access the Company’s regulatory filings on the SEDAR website at www.sedar.com and on the EDGAR website at www.sec.gov.

Stock Information

Exchange Price
TSX: ONC $ CAD
OTCQX: ONCYF $ USD

VIEW ALL STOCK INFORMATION

Financials

Access our quarterly and year-end financial statements, MD&A, information circulars and annual reports.

VIEW ALL FINANCIALS

Corporate Governance

Oncolytics Biotech Inc. believes in a transparent and forward-facing approach to business.

VIEW ALL DOCUMENTS

Letter to Stakeholders

Q1 Letter to Shareholders

Analyst Coverage

Read More